Technetium-99m red blood cell labeling in patients treated with doxorubicin.
Radionuclide angiography is useful in monitoring cardiotoxicity of doxorubicin, but in vivo RBC labeling in these patients is believed to be poorer than that in general patients. The left ventricle-to-background activity ratio (R) was not significantly lower in patients treated with doxorubicin (3.24 +/- 1.15, N = 13) than in control patients (3.89 +/- 1.60, N = 14). With both modified in vivo and in vitro labeling, R was significantly improved in patients treated with doxorubicin (4.37 +/- 0.91, N = 8, and 4.37 +/- 1.22, N = 13, respectively). However, with the modified in vivo method, labeling efficiency remained a function of hematocrit, whereas the in vitro method removed this dependency. Both modified in vivo and in vitro labeling result in improved image quality over in vivo labeling in patients treated with doxorubicin, and the choice of method can be based on other factors.
Ballinger
J R
JR
Division of Nuclear Medicine, Ottawa Civic Hospital, Ontario, Canada.
Gerson
B
B
Gulenchyn
K Y
KY
Ruddy
T D
TD
Davies
R A
RA
D004317:Doxorubicin / Q000494:pharmacology*; D004347:Drug Interactions; D004912:Erythrocytes / Q000000981:diagnostic imaging*; D006801:Humans; D011877:Radionuclide Imaging; D013318:Stroke Volume; D013667:Technetium / Q000494:pharmacology*
D013667:Technetium; D004317:Doxorubicin